In the high-stakes world of modern medicine, we are currently witnessing a structural realignment of the pharmaceutical industry. If the early 2010s were defined by the "patent cliff" of small-molecule blockbusters like Lipitor, 2026 marks the dawn of a far more complex era. This is the year of the biological "super-cliff," where the Biosimilars M